VerImmune to Present at Biotech Showcase™ 2020 in San Francisco

VerImmune, an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection to addressing unmet needs in Oncology, announced today that Joshua Wang, Founder & CEO of VerImmune will present at Biotech Showcase 2020.

Date: Wednesay, January 15, 2020
Time: 10:30 a.m. PST
Location: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco
Track:  Yosemite A (Ballroom Level)

About VerImmune

VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirectors (AIRTM) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. This unique mechanism of action allows differentiation within the competitive Immuno-Oncology market. Importantly, it potentially changes the treatment paradigm for many patients who have untreatable cancers due to limited options or resistance. The Company initially raised a seed round and demonstrated proof-of-concept in preclinical studies for its first product candidate, VERI-101; it is planning in 2020 to move VERI-101 to an IND. For more information: www.verimmune.com